Compare AbbVie Inc (ABBV) vs Chevron Corp (CVX) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Chevron (CVX) trades at $168.1, down 0.66% on the day, amid a broader technical bearish signal. The stock shows mixed fundamentals with declining revenue and net income over recent years, though it has consistently beaten earnings expectations. A strong $1.78 dividend is scheduled for payment in June 2026. Wall Street sentiment remains predominantly bullish, with a consensus price target of $209 representing significant upside, countering the current technical weakness.

The investment case balances a high analyst buy rating and attractive dividend against fundamental profit margin compression and exposure to volatile oil prices. Key risks include execution of major projects like the $13.8B Argentina investment and geopolitical tensions affecting supply chains. The stock's current price sits near immediate technical support at $167.